Nidom Reviany V, Indrasari Setyarina, Normalina Irine, Nidom Astria N, Afifah Balqis, Dewi Lestari, Putra Andra K, Ansori Arif N M, Kusala Muhammad K J, Alamudi Mohammad Y, Nidom Chairul A
Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, Surabaya, Indonesia.
Riset AIRC Indonesia, Surabaya, Indonesia.
Bull Natl Res Cent. 2021;45(1):200. doi: 10.1186/s42269-021-00657-0. Epub 2021 Nov 21.
Indonesia has started the big project of COVID-19 vaccination program since 13 January 2021 by employing the first shot of vaccine to the President of Indonesia as the outbreak and rapid transmission of COVID-19 have endangered not only Indonesian but the global health and economy. This study aimed to investigate the full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates as of 12 January 2021.
All data of the isolates were extracted from the Global Initiative on Sharing All Influenza Data (GISAID) EpiCoV database. CoVsurver platform was employed to investigate the full-length genome mutation analysis of all isolates. This study also focused on the phylogeny analysis in unlocking the mutation of S protein in Indonesian SARS-CoV-2 isolates. WIV04 isolate that was originated from Wuhan, China was used as the virus reference according to the CoVsurver default. The result showed that a full-length genome mutation analysis of 166 Indonesian SARS-CoV-2 isolates was successfully generated. Every single mutation in S protein was described and then visualized by utilizing BioRender platform. Furthermore, it also found that D614G mutation appeared in 103 Indonesian SARS-CoV-2 isolates.
To sum up, this study helped to observe the spread of COVID-19 transmission. However, it also proposed that the epidemiological surveillance and genomics studies might be improved on COVID-19 pandemic in Indonesia.
The online version contains supplementary material available at 10.1186/s42269-021-00657-0.
自2021年1月13日起，印度尼西亚启动了新冠疫苗接种大型项目，首先为印度尼西亚总统接种了疫苗，因为新冠疫情的爆发和快速传播不仅危及印度尼西亚，也危及全球健康和经济。本研究旨在对截至2021年1月12日的166株印度尼西亚严重急性呼吸综合征冠状病毒2（SARS-CoV-2）分离株进行全基因组突变分析。
所有分离株的数据均从全球共享所有流感数据倡议组织（GISAID）的EpiCoV数据库中提取。采用CoVsurver平台对所有分离株进行全基因组突变分析。本研究还聚焦于系统发育分析，以揭示印度尼西亚SARS-CoV-2分离株中S蛋白的突变情况。根据CoVsurver的默认设置，将源自中国武汉的WIV04分离株用作病毒参考。结果显示，成功生成了166株印度尼西亚SARS-CoV-2分离株的全基因组突变分析结果。描述了S蛋白中的每一个突变，然后利用BioRender平台进行可视化展示。此外，还发现103株印度尼西亚SARS-CoV-2分离株中出现了D614G突变。
综上所述，本研究有助于观察新冠病毒的传播情况。然而，它也提出在印度尼西亚的新冠疫情中，流行病学监测和基因组学研究可能需要改进。
在线版本包含可在10.1186/s42269-021-00657-0获取的补充材料。
